Chronic Heart Failure – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of CHF for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this content.
Clarivate Epidemiology’s CHF forecast will answer the following questions:
- Of all people diagnosed with CHF, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CHF over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following CHF subpopulations:
- Diagnosed prevalent cases of CHF by comorbid atrial fibrillation (AF).
- Diagnosed prevalent cases of CHF by comorbid chronic obstructive pulmonary disease (COPD).
- Diagnosed prevalent cases of CHF by comorbid diabetes.
- Diagnosed prevalent cases of CHF by comorbid hypertension.
- Diagnosed prevalent cases of CHF by comorbid coronary heart disease (CHD).
- Diagnosed prevalent cases of CHF by comorbid dyslipidemia.
- Diagnosed prevalent cases of CHF by history of myocardial infarction (MI).
- Diagnosed prevalent cases of CHF by history of stroke.
- Diagnosed prevalent cases of CHF by comorbid obesity.
- Diagnosed prevalent CHF cases by New York Heart Association (NYHA) functional classification status.
- Diagnosed prevalent cases of CHF characterized by reduced ejection fraction (EF).
- Diagnosed prevalent cases of CHF characterized by preserved or mid-range EF.
- … and more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Chronic Heart Failure - Epidemiology - Mature Markets Data
- Introduction
- Key Findings
- Diagnosed Prevalence of Chronic Heart Failure per 1,000 People Aged 20+ in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Chronic Heart Failure Over the Next 20 Years
- Analysis of Diagnosed Prevalent Cases of Chronic Heart Failure by Ejection Fraction
- Analysis of the Diagnosed Prevalent Cases of Chronic Heart Failure by Drug-Treated Status
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Prevalent Cases
- Diagnosed Prevalent Cases by New York Heart Association Functional Classification
- Diagnosed Prevalent CHF Cases by Comorbid Atrial Fibrillation Status
- Diagnosed Prevalent CHF Cases by Chronic Obstructive Pulmonary Disease Status
- Diagnosed Prevalent CHF Cases by Comorbid Coronary Heart Disease Status
- Diagnosed Prevalent CHF Cases by Comorbid Diabetes
- Diagnosed Prevalent CHF Cases by Comorbid Dyslipidemia Status
- Diagnosed Prevalent CHF Cases Classified by History of Myocardial Infarction
- Diagnosed Prevalent CHF Cases Classified by History of Stroke
- Diagnosed Prevalent CHF Cases by Comorbid Hypertension Status
- Diagnosed Prevalent CHF Cases by Comorbid Obesity Status
- Diagnosed Prevalent Cases of Chronic Heart Failure Classified by Ejection Fraction
- Percentage Drug-Treated
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Chronic Heart Failure
- Studies Excluded from the Analysis of Chronic Heart Failure
- Risk/Protective Factors
- Risk/Protective Factors for Chronic Heart Failure
- Abbreviations
- Glossary
- Literature Review
- Introduction
Sunali Goonesekera, S.M., is a senior epidemiologist at Clarivate. Previously, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.